Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis.
- Published In:
- Current medical research and opinion, 36(11), 1861-1872 (2020)
- Authors:
- Miller, Paul D, Bilezikian, John P, Fitzpatrick, Lorraine A, Mitlak, Bruce, McCloskey, Eugene V, Cosman, Felicia, Bone, Henry G
- Database ID:
- RPEP-04999
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-04999APA
Miller, Paul D; Bilezikian, John P; Fitzpatrick, Lorraine A; Mitlak, Bruce; McCloskey, Eugene V; Cosman, Felicia; Bone, Henry G. (2020). Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis.. Current medical research and opinion, 36(11), 1861-1872. https://doi.org/10.1080/03007995.2020.1824897
MLA
Miller, Paul D, et al. "Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis.." Current medical research and opinion, 2020. https://doi.org/10.1080/03007995.2020.1824897
RethinkPeptides
RethinkPeptides Research Database. "Abaloparatide: an anabolic treatment to reduce fracture risk..." RPEP-04999. Retrieved from https://rethinkpeptides.com/research/miller-2020-abaloparatide-an-anabolic-treatment
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.